Literature DB >> 12851022

Predicting completion of outpatient opioid detoxification with clonidine.

Stephen Strobbe1, Kirk J Brower, Luke W Galen.   

Abstract

Completion rates for outpatient opioid detoxification with clonidine generally range from 20-40%, but few studies have examined the correlates of successful completion. Of 29 consecutive patients, we compared those who completed detoxification with clonidine (n=12) to those who did not (n=17). Patients who completed treatment were significantly (p< 0.05) more likely to depend on opioids other than heroin, have private health insurance, and report low levels of subjective withdrawal symptoms. Patients with two or three of these characteristics were about seven times more likely to complete treatment than patients with none or one. Although it may not detoxify most opioid-dependent patients, clonidine will likely play a continued role in selected patients when a non-narcotic agent is desirable. The study findings may help target patients who could benefit the most from outpatient clonidine detoxification.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12851022

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  6 in total

1.  Searching for evidence of genetic mediation of opioid withdrawal by opioid receptor gene polymorphisms.

Authors:  Jermaine D Jones; Rachel R Luba; Jonathan L Vogelman; Sandra D Comer
Journal:  Am J Addict       Date:  2015-12-21

2.  Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence.

Authors:  Douglas M Ziedonis; Leslie Amass; Marc Steinberg; George Woody; Jonathan Krejci; Jeffrey J Annon; Allan J Cohen; Nancy Waite-O'Brien; Susan M Stine; Dennis McCarty; Malcolm S Reid; Lawrence S Brown; Robert Maslansky; Theresa Winhusen; Dean Babcock; Greg Brigham; Joan Muir; Deborah Orr; Betty J Buchan; Terry Horton; Walter Ling
Journal:  Drug Alcohol Depend       Date:  2008-09-20       Impact factor: 4.492

3.  Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.

Authors:  Kelly E Dunn; D Andrew Tompkins; George E Bigelow; Eric C Strain
Journal:  JAMA Psychiatry       Date:  2017-09-01       Impact factor: 21.596

4.  Programmable transdermal clonidine delivery through voltage-gated carbon nanotube membranes.

Authors:  Caroline Strasinger; Kalpana S Paudel; Ji Wu; Dana Hammell; Raghotham R Pinninti; Bruce J Hinds; Audra Stinchcomb
Journal:  J Pharm Sci       Date:  2014-05-01       Impact factor: 3.534

5.  Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model.

Authors:  Thomas F Northrup; Angela L Stotts; Charles Green; Jennifer S Potter; Elise N Marino; Robrina Walker; Roger D Weiss; Madhukar Trivedi
Journal:  Addict Behav       Date:  2014-09-28       Impact factor: 3.913

6.  Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes.

Authors:  Kelly E Dunn; Elise M Weerts; Andrew S Huhn; Jennifer R Schroeder; David Andrew Tompkins; George E Bigelow; Eric C Strain
Journal:  Addict Biol       Date:  2018-10-08       Impact factor: 4.280

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.